Build your own keyword analysis with our tools
SEO Report
Server Infos
Backlinks

HTML Analysis

Page Status
 

Found

Highlighted Content
Title

Addex Therapeutics : about addex

Description

Keywords

H1

H2

H3

H4

H5

Text Analysis

Cloud of Keywords from all content
High relevance
 

addex allosteric phase disease therapeutics clinical switzerland dipraglurant drug modulator data dyskinesia positive company discovery parkinson’s receptor levodopa-induced testing small preclinical pharmaceuticals molecule reports oral parkinson adxn treatment pam development biotech announces study financial model drugs adx71441 modulators announced studies diseases swiss therapeutic lead track leading pioneering initiate mglu5 mglur4

Medium relevance
 

negative major adx71149 pipeline alcohol modulation-based treat mglur2 michael gpcrs foundation march receptors fox year top-line awarded platform anxiety plasma report reinforces wins alzheimer reduces ceo partner patients including focus european grant trial disorder modulation gaba-b trials efficacy effective fund today dose-dependent mglur5 plans pd-lid

Low relevance
 

year top-line awarded platform anxiety plasma report reinforces wins alzheimer reduces ceo partner patients including focus european grant trial disorder modulation gaba-b trials efficacy effective fund today dose-dependent mglur5 plans pd-lid non-human primate august biomarker international cash private targets therapeutics addex adx71441 adx71441 concentrations europabio’s expects approach compounds brussels occupancy targeting human investors composition target issuance matter patent turned annual funding levodopa depressive october in-man multiple urgency motor april dyer september intake structures application approval entering pre-clinical innovative upside selective partnered asset treating steps restructuring unmet neurodegenerative proprietary biological conventional undruggable glutamate geneva adx48621 effects antagonist g-protein gaba-br coupled schizophrenia programs charity developed

Very Low relevance
 
non-human primate august biomarker international cash private targets therapeutics addex adx71441 adx71441 concentrations europabio’s expects approach compounds brussels occupancy targeting human investors composition target issuance matter patent turned annual funding levodopa depressive october in-man multiple urgency motor april dyer september intake structures application approval entering pre-clinical innovative upside selective partnered asset treating steps restructuring unmet neurodegenerative proprietary biological conventional undruggable glutamate geneva adx48621 effects antagonist g-protein gaba-br coupled schizophrenia programs charity developed experience chf36 equivalents being developed highlightscash -addex diversifies feb therapeutics geneva mednous results financial feels afford platforms approaches emerging gpcr timelines comparable solve pharmaceutical soluble refining modulation-focused programme quickly addex prioritize operations pharmaceuticals’ bharatt decision-making support chowrira december indicationsgeneva models publication $900 caused seminal greater movement symptoms addex insight side the reducing proved pay disease addex homecontactsitemap wednesday geneva 2012 positive spur inhibitor short deal in hopes dopamine daily shrinking 2012gaba-br pool indfiling everything this objectives fundraising demonstrated addex tolerability achievedsafety bladder program economic sheet 18june congress geneva society’s symptoms geneva pink slowdown overactive june trial 23 hunt reminder processes dissipating slow demand healthcare pharma functions cost-cutting risk perspective groups recaps publicly chorea unique subtype torture while companies metabotropic multitude involved treatments award” debilitating ”most causing making cornerstone tainted eventually treats winner award critical europabio neurotransmitter therapy glutamate video award geneva event coverage usdin extends lined sources financing weeks return basics signals sees strategy pair actor’s cover trial a based c&en story x-ray popular progress the crystal toxicity month research biocentury bvf less halting program washington investment runway editor chf discusses hood corner liver apm berlin failure compound katie week biocentury week’s drivers validates assets geneva monetize organization produced growth gamma-aminobutyric confirms modelthe hormone restructure intends arthritis rheumatoid inflammation tnfr1 history2012 completes shareholders company preserve capture capturing acid gaba dependence chronic chief co-founder gabab cta dipraglurant dipraglurant safety deliver receives role geneva consulting correlates demonstrated dipragluant modulating exposure links external transition cfo pharmacological huntington’s alzheimer’s “orthosteric” advantages confer intendedtargetand address proteins rtks kinases tyrosine methods exquisitely called addexexecutive aboutr&dinvestorscareers realm expanding managementboard directors addex oralsmall class emerging pioneeringdiscovery cytokine tnf glp1r disorders bladder foroveractive type diabetes trkb identify addition depression advancing janssen attractive widelyrecognized targetshave superfamily medical remained investigated products company’s inaccessible dystonias geneva normalizes updates adx71441- addex - data drinking guidance raises horizon youtube addex institutional placement $10 binge patients addex addressing allostery charcot-marie-tooth transgenic cns diseases addex cracking paving throughput high collaborators develop outre-atlantique investisseurs intérêt regain direction plaide symptoms geneva patient doses sous-évalutation bénéficié titre mglur7geneva characterize diseases grant psychiatric sclerosis model a genève addex américain soutien sclerosisgeneva 2013 addex dystonia dipraglurant dyskinesia geneva neurology academy american shareholders approve meeting geneva general proposals board meeting presentation validated dysfunction cholinergic striatal primary generalized dystonias dyt1 dystonia torsion research grant link indication resources highlights biology submit orphan types relevant abnormalities europe structural functional adenosine advance viva partners receptor partnership demonstrate integrating modulator-based accelerate results geneva

Highlighted Content Analysis

Cloud of Keywords from all content
High relevance
 

Medium relevance
 

Low relevance
 

addex

Very Low relevance
 
addex therapeutics